ICU Overview

SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).

Wall Street analysts forecast ICU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SeaStar Medical Holding Corp revenue for the last quarter amounts to 183.00K USD, increased 169.12

SeaStar Medical Holding Corp. EPS for the last quarter amounts to -1.32 USD, decreased -87.96

SeaStar Medical Holding Corp (ICU) has 19 emplpoyees as of March 11 2026.

Today ICU has the market capitalization of 10.22M USD.